Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 EV-to-EBITDA is 77.74 as of Aug. 09, 2026, which is 65% above its 10-year median of 47.23. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 737 Drug Manufacturers companies, Sai Parenteral's ranks worse than 93.49% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sai Parenteral's's enterprise value is ₹27,006 Mil.
Sai Parenteral's's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was ₹347 Mil. Therefore, Sai Parenteral's's EV-to-EBITDA for today is 77.74.
The historical rank and industry rank for Sai Parenteral's's EV-to-EBITDA or its related term are showing as below:
NSE:SAIPARENT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 36.67 Med: 47.23 Max: 77.74
Current: 77.74
During the past 3 years, the highest EV-to-EBITDA of Sai Parenteral's was 77.74. The lowest was 36.67. And the median was 47.23.
NSE:SAIPARENT's EV-to-EBITDA is ranked worse than 93.49% of 737
companies
in the Drug Manufacturers industry
Industry Median: 13.28
vs NSE:SAIPARENT: 77.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sai Parenteral's (NSE:SAIPARENT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sai Parenteral's's PE Ratio (TTM) for today is calculated as:
Sai Parenteral's's share price for today is ₹569.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.374.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sai Parenteral's's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's EV-to-EBITDA Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
EV-to-EBITDA
0.00
0.00
0.00
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
EV-to-EBITDA
0.00
0.00
0.00
0.00
NSE:SAIPARENT vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's EV-to-EBITDA falls into.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was ₹347 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a EV-to-EBITDA of 77.74 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sai Parenteral's. This is 65% above median its historical median of 47.23. Over the past decade, Sai Parenteral's' EV-to-EBITDA has ranged from 36.67 to 77.74. According to the industry distribution chart, Sai Parenteral's ranks #689 out of 737 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Sai Parenteral's' EV-to-EBITDA too high?
Sai Parenteral's' current EV-to-EBITDA of 77.74 is 65% above median its 10-year median of 47.23. Over the past 10 years, this metric has ranged from a low of 36.67 to a high of 77.74. The Drug Manufacturers industry median EV-to-EBITDA is 13.28. Sai Parenteral's' value of 77.74 is 485.4% above this industry median. Based on the distribution chart, Sai Parenteral's ranks #689 out of 737 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #689 out of 737 companies for EV-to-EBITDA. This places Sai Parenteral's in the lower half of its industry. The industry median EV-to-EBITDA is 13.28. Sai Parenteral's' value of 77.74 is 485.4% above this benchmark. Historically, Sai Parenteral's' own EV-to-EBITDA has ranged from 36.67 to 77.74 over the past decade. While the company's 10-year median is 47.23 vs. the industry median of 13.28, Sai Parenteral's has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.28, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current EV-to-EBITDA of 77.74 is 485.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sai Parenteral's. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current EV-to-EBITDA is 77.74, which is 65% above median its own 10-year median of 47.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current EV-to-EBITDA of 77.74. The current EV-to-EBITDA is 77.74, which is 65% above median its 10-year median of 47.23 and 485.4% above the Drug Manufacturers industry median of 13.28. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current EV-to-EBITDA is 77.74 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
